

REMARKS

After entry of the present amendment, claims 1-17 will be pending in the application. Claims 1-17 are allowed. Claims 18-24 have been cancelled without prejudice to the presentation of these claims in a continuation application. Claim 17 has been amended to correct a typographical error. No new matter has been introduced by this amendment.

Response to rejection of claim 18-24 under 35 U.S.C. § 102

Claims 18-24 stand rejected as allegedly anticipated under 35 USC 102(e) by Aronhime *et al.*, and under 35 USC 102(a) by US 6,410,520, or under 35 USC 102(b) by WO 01/56983.

This rejection is moot in the present application because claims 18-24 have been cancelled. Applicants do not concede the correctness of these claim rejections. The present amendment is submitted to expedite the allowance of the claims remaining in the application. Claims 18-24 are cancelled without prejudice to Applicants' pursuance of this subject matter in one or more continuing applications.


Applicants respectfully submit that, in light of the amendment and remarks herein, the present Application is in condition for allowance.

This Amendment is being timely filed in view of the accompanying Petition under 37 CFR 1.136 for a two-month extension of time, which extends the time for a response to the Office Action through and to November 7, 2007.

Please charge the fee for the ^{two} ~~three~~-month extension, and any other fees, ~~including the~~ ~~PCE filing fee~~, which may be required for the filing of this response, to Kenyon & Kenyon, LLP Deposit Account No. 11-0600.

Respectfully Submitted,

Dated: October 26, 2007

By: 
Timothy W. Davenport
Reg. No. 47,515

TEVA PHARMACEUTICALS
1090 Horsham Rd. P.O. 1090
North Wales, PA 19454
USA
Phone: 215-293-6519
CUSTOMER NUMBER _____